In a presentation during the American Conference Institute’s Summit on Biosimilars, held June 25-27 in New York, New York, Laura Sim, JD, senior counsel at Amgen, and Vishal Gupta, JD, partner at Steptoe & Johnson LLP, discussed various naming and labeling considerations that stakeholders need to consider for biosimilars.
The naming and labeling of biosimilar and biologic products has previously caused controversy throughout the industry. The FDA officially released a finalized naming and labeling guideline in January 2017, and started to implement the new approach in November 2017.
The guideline constitutes the non-proprietary name of approved biosimilars and biologics to include a 4-letter suffix, devoid of meaning. In addition, the policy requires previously approved reference products to include the suffix as well; however, to date, no biologic approved prior to the release of the finalized guidance has been retroactively amended.
In a presentation during the American Conference Institute’s Summit on Biosimilars, held June 25-27 in New York, New York, Laura Sim, JD, senior counsel at Amgen, and Vishal Gupta, JD, partner at Steptoe & Johnson LLP, discussed various naming and labeling considerations to take into account.
Sim began her presentation by noting Amgen’s positive opinion of the FDA’s naming regulations because it “promotes patient safety and success of the market and will also enhance pharmacovigilance and the traceability of a drug.”
An important area to watch going forward in the process will be the naming of any potential interchangeable products, as well as how the FDA will address the addition of suffixes to already marketed products. Amgen, she said, has recommended a few key action items to the FDA to ensure the smooth implementation of suffixes to postmarketed products, such as:
Gupta then led a discussion around labeling practices for biosimilar medicines. There has been some litigation around what a biosimilar medicine should or should not legally include within its label. The FDA put out a draft guidance document in March 2016 specifying that a biosimilar drug label must contain:
Notably, the label guidance does not include the requirement of an interchangeability statement, biosimilarity study data, or statements about any extrapolation of data. “Going forward, I expect that the final guidance will be pretty consistent with the draft guidance the FDA has issued,” said Gupta.
Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings
May 16th 2024Two posters from the Academy of Managed Care Pharmacy’s annual meeting provided hope that despite low uptake so far, adalimumab biosimilars can deliver on the promise of comparable safety and efficacy with the originator in multiple disease states, as well as cost savings.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars
May 2nd 2024Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.